BioCentury
ARTICLE | Company News

Jennerex Biotherapeutics, Transgene deal

November 23, 2015 8:00 AM UTC

SillaJen Inc. (Busan, South Korea), which acquired Jennerex in 2014, and Transgene amended a 2010 deal in which Jennerex granted Transgene exclusive rights to develop and commercialize Pexa-Vec in Europe, the Commonwealth of Independent States (CIS) and the Middle East. SillaJen will regain rights to the recombinant vaccinia virus (addition of GM-CSF and deletion of thymidine kinase) in the Middle East, Russia, Ukraine, Belarus and Turkey. SillaJen will also assume responsibility for conducting the Phase III PHOCUS trial of Pexa-Vec to treat hepatocellular carcinoma (HCC). The trial is slated to begin by year end. In return, Transgene will pay $6 million to SillaJen over four years. ...